BHVN Latest Press Releases

-- June 30, 2026 --

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator PRNewswire 7:30 AM

-- June 29, 2026 --

Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease PRNewswire 7:30 AM

-- June 1, 2026 --

Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation PRNewswire 7:30 AM

-- May 27, 2026 --

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy PRNewswire 7:30 AM

-- May 26, 2026 --

Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile PRNewswire 7:30 AM

-- May 4, 2026 --

Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results PRNewswire 4:02 PM

-- March 19, 2026 --

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment PRNewswire 7:30 AM

-- March 2, 2026 --

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results PRNewswire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software